Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta

NCT05312697 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision not related to safety concerns

Conditions

Osteogenesis Imperfecta

Interventions

BIOLOGICAL: Setrusumab

Sponsor

Ultragenyx Pharmaceutical Inc

Collaborators

[object Object]